People · Operator
Named in public records as an officer, director or promoter · active 2008–2022 · Biotechnology, Other Health Care, Medical Devices, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| TELA Bio, Inc. | — | Biotechnology | Series C | $104.8M | $435.1M | 2017 |
| Encore Dermatology, Inc. | — | Other Health Care | Series B | $89.6M | $729.9M | 2019 |
| Onkos Surgical, Inc. | — | Medical Devices | Series B | $72.3M | $595.1M | 2017 |
| Sprout2 Inc. | — | Pharmaceuticals | Series B | $66.0M | $62.0M | 2017 |
| NovaSom, Inc | — | Other Health Care | Series B | $53.9M | $82.0M | 2017 |
| Colorescience Inc | — | Other Health Care | Series B | $51.2M | $66.5M | 2017 |
| Greenbrook TMS Inc. | — | Other Health Care | Series B | $50.6M | $187.0M | 2022 |
| Sleep Solutions Inc | — | Other Health Care | Series B | $20.0M | $443.1M | 2009 |
| Oceana Therapeutics, Inc. | — | Pharmaceuticals | Seed | $3.0M | $114.1M | 2008 |
Adele Oliva at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Adele Oliva on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Adele C. Oliva | 3 | 5 |
| Paul Touhey | 2 | 3 |
| Antony Koblish | 2 | 3 |
| Michael Brown | 1 | 34 |
| Ryan Drant | 1 | 24 |
| David F Hale | 1 | 16 |
| Stephen Bloch | 1 | 15 |
| Christopher Smith | 1 | 15 |
| Annette Campbell-White | 1 | 11 |
| Brian Halak | 1 | 10 |
| Alex Morgan | 1 | 10 |
| Juliet Bakker | 1 | 9 |
| Kevin Rakin | 1 | 7 |
| Robert Higgins | 1 | 7 |
| Josh Baltzell | 1 | 7 |
| Brian H. Dovey | 1 | 7 |
| Robert More | 1 | 7 |
| James A. Datin | 1 | 6 |
| W. Robert Dahl | 1 | 6 |
| Adrienne Graves | 1 | 6 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.